ArticleInternational journal of radiation oncology, biology, physics2025
Associations Between G8 Geriatric Screening Score, Charlson Comorbidity Index, AI-Based Age Phenotype, and Overall Survival in Older Adults With Stage I-II Non-Small Cell Lung Cancer.
Article in International journal of radiation oncology, biology, physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic utility of the Charlson comorbidity index in pancreatic cancer: a systematic review and meta‑analysis.World journal of surgical oncology · 2026Pooled it
- Risk-adapted SBRT ([Formula: see text]) for recurrent lung-only metastases in patients with frailty or ultracentral anatomy.Radiation oncology (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposeComprehensive geriatric assessment can identify older adult oncology patients at high risk for adverse outcomes, but is variably feasible. Therefore, we assessed whether an abridged geriatric vulnerability model incorporating abstracted G8 score (G8), Charlson Comorbidity Index (CCI), and FaceAge (an AI-based aging measure) was associated with all-cause mortality or falls risk in patients undergoing stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC).
methodsWe reviewed the records of 708 patients aged ≥65 years with stage I-II NSCLC treated with SBRT from June 1, 2009, to March 31, 2023. We abstracted demographics, functional status (Eastern Cooperative Oncology Group [ECOG] score), oncologic history, G8, CCI, falls risk (Morse Fall Scale or Strategies to Reduce Injuries and Develop Confidence in Elders screening tool), and time-to-death. FaceAge was calculated using AI-based facial analysis of SBRT simulation photographs. We examined associations between a vulnerability model incorporating G8, CCI, and FaceAge, and all-cause mortality and falls risk, using Cox and regression models adjusted for age, sex, stage, ECOG, and significant covariates (P < .10).
resultsPatients (median age, 76.2 years; 60.7% female; median stage IA), commonly had functional limitations (median ECOG, 1; IQR, 1-2), multimorbidity (median CCI, 7; IQR, 6-8), poor G8 scores (median, 12.5; IQR, 11.5-13.5), and elevated biological FaceAge (median 2.6 years above chronological age). In an adjusted Cox regression model, worse performance on all 3 geriatric vulnerability measures was independently associated with higher all-cause mortality (hazard ratio [HR]
conclusionsAmong older adults with early-stage NSCLC, a multimodal vulnerability measure leveraging routinely collected data was associated with all-cause mortality, identifying patients who might benefit from additional services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.